Value through Innovation26 November 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


European Commission grants Lilly and Boehringer Ingelheim's insulin glargine product marketing authorisation in Europe

- For Non-U.S. and Non-U.K. Media

Diabetes: Boehringer Ingelheim and Eli Lilly and Company announce data on portfolio to be presented at the 50th EASD Annual Meeting

- For Non-US and Non-UK Media

Nintedanib* slowed disease progression in IPF independent of patients’ lung function impairment at baseline

- For media outside UK, US and Canada

European Respiratory Society International Congress 2014
TONADO™ - further lung function and quality of life benefits with tiotropium + olodaterol Respimat® FDC* in COPD

- For media outside the US, the UK and Canada

Asthma: new indication for Spiriva® (tiotropium) Respimat®* in the EU may offer millions of adults a significant advance in asthma care


- For Media outside the US, the UK & Canada only

ESC Congress 2014 Hot Line Session: Favourable effect of Pradaxa® on kidney function over time compared to warfarin

- Non-US/Non-UK/Non-Canadian Media

Extensive experience in clinical practice and expanding research programme support use of Pradaxa® for clot prevention

- For Non-US/Non-UK/Non-Canadian Media

Boehringer Ingelheim Animal Health sees freshly mixed swine vaccines as its way forward


Boehringer Ingelheim to present comprehensive data supporting broad respiratory portfolio in COPD, asthma and IPF at ERS 2014

- For media outside UK, US and Canada

New Pradaxa® data to be presented at the ESC Congress 2014

- For Non-US/Non-UK/Non-Canadian Media

Boehringer Ingelheim Animal Health celebrates 20 years of PRRS control and innovation


First patients enrolled in study to evaluate dabigatran etexilate after PCI with stenting

- For Non-US/Non-UK/Non-Canadian Media

First half year 2014: Boehringer Ingelheim meets challenges


Boehringer Ingelheim receives two FDA approvals

- For Non-US/Non-UK media only

Pradaxa® (dabigatran etexilate) Video Statement

- For media outside UK, U.S. and Canada

Efficacy and Safety Profile of Pradaxa® (dabigatran etexilate) Repeatedly Confirmed

- For media outside UK, U.S. and Canada

Boehringer Ingelheim Establishes a Research Alliance with the University of Toronto, the Toronto-based University Health Network and the Mount Sinai Hospital to investigate new therapeutic concepts in the field of ubiquitin signalling biology


Boehringer Ingelheim’s investigational therapy nintedanib* receives the first FDA breakthrough therapy designation in IPF

- For non-US media only